Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care—Registry data from an outcomes research project of the German Testicular Cancer Study Group
详细信息 查看全文
- 作者：Christoph Seidel ; M.D.a ; 1 ; c.seidel@uke.de" class="auth_mail" title="E-mail the corresponding author ; Karin Oechsle ; M.D.a ; 1 ; Anja Lorch ; M.D.b ; Annette Dieing ; M.D.c ; Marcus Hentrich ; M.D.d ; Mareike Hornig ; M.D.e ; Viktor Grü ; nwald ; M.D.e ; Richard Cathomas ; M.D.f ; Johannes Meiler ; M.D.g ; Maike de Wit ; M.D.h ; Carsten Bokemeyer ; M.D.a
- 关键词：Cisplatin-refractory germ cell cancer ; Gemcitabine ; Oxaliplatin ; Paclitaxel ; GOP chemotherapy
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：34
- 期：4
- 页码：168.e21-168.e28
- 全文大小：379 K
文摘
- •
Efficacy and safety of the GOP regimen outside clinical trials were investigated.
- •
Long-term OS of>2 years was achieved in 21% of the patients.
- •
The GOP regimen is feasible in heavily pretreated patients.
- •
Our results confirm the data from the previous phase II study.